Compare CFR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFR | CYTK |
|---|---|---|
| Founded | 1868 | 1997 |
| Country | United States | United States |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | CFR | CYTK |
|---|---|---|
| Price | $140.07 | $65.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 18 |
| Target Price | ★ $142.31 | $88.50 |
| AVG Volume (30 Days) | 433.7K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $9.72 | $6.88 |
| Revenue Next Year | $4.70 | $308.26 |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $101.76 | $29.31 |
| 52 Week High | $148.97 | $70.98 |
| Indicator | CFR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 55.10 |
| Support Level | $124.16 | $59.12 |
| Resistance Level | $140.27 | $65.27 |
| Average True Range (ATR) | 2.67 | 2.46 |
| MACD | 0.99 | 0.59 |
| Stochastic Oscillator | 98.70 | 62.04 |
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.